July 16 (Reuters) - The U.S. Food and Drug Administration's staff reviewers on Wednesday raised efficacy concerns over Otsuka Pharma's 4578.T combination treatment for adults with post-traumatic stress disorder (PTSD), citing inconsistent trial results and a modest treatment effect that may not be clinically meaningful.
(Reporting by Siddhi Mahatole and Mariam Sunny in Bengaluru; Editing by Shailesh Kuber and Shreya Biswas)
((siddhi.mahatole@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.